355 related articles for article (PubMed ID: 21677673)
21. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
[TBL] [Abstract][Full Text] [Related]
22. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
23. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
24. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
25. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
Bakris G; Yang YF; Pitt B
Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
27. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
28. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
29. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
31. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid antagonists in chronic kidney disease.
Dhaybi OA; Bakris G
Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):50-55. PubMed ID: 27753685
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
[TBL] [Abstract][Full Text] [Related]
34. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists.
Verdalles U; Goicoechea M; García de Vinuesa S; Torres E; Hernández A; Verde E; Pérez de José A; Luño J
Nefrologia (Engl Ed); 2020; 40(1):65-73. PubMed ID: 31451203
[TBL] [Abstract][Full Text] [Related]
35. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
36. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Hou J; Xiong W; Cao L; Wen X; Li A
Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Omae K; Ogawa T; Nitta K
Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
[TBL] [Abstract][Full Text] [Related]
39. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
40. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
Obialo CI; Ofili EO; Mirza T
Am J Cardiol; 2002 Sep; 90(6):663-5. PubMed ID: 12231103
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
